Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

作     者：Jiang-Yi Wang Guo-Peng Yu Long Li Guo-Wen Lin Ding-Wei Ye Jiang-Yi Wang;Guo-Peng Yu;Long Li;Guo-Wen Lin;Ding-Wei Ye

作者机构：Department of UrologyFudan University Shanghai Cancer Center270 Dong'an RoadShanghai 200032China Department of OncologyShanghai Medical CollegeFudan UniversityShanghai 200032China Department of UrologyShanghai Ninth People's HospitalShanghai Jiaotong University School of MedicineShanghai 200011China 

出 版 物：《Military Medical Research》 (军事医学研究（英文版）)

年 卷 期：2022年第9卷第6期

页      面：754-756页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China (81902574) the Shanghai Basic Research Program (19JC1411600) the Shanghai Natural Science Foundation (21ZR1414500) the Shanghai Sailing Program (19YF1409800) 

主　　题：Metastatic castration-resistant prostate cancer PSA decline PSA velocity Overall survival Time to PSA progression 

摘      要：Dear Editor,Although the incidence of prostate cancer(PCa) has decreased in recent decades in Western countries, it has gradually increased in China due to the increasingly longer life expectancy and more popular westernized diet[1].